Investing.com - Core Laboratories (NYSE: CLB) reported third quarter EPS of $0.25, $0.03 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $134.4M versus the consensus estimate of $139.66M.
Guidance
Core Laboratories sees Q4 2024 EPS of $0.20-$0.25 versus the analyst consensus of $0.24.
Core Laboratories sees Q4 2024 revenue of $128.50M-$135.50M versus the analyst consensus of $134.00M.
Core Laboratories's stock price closed at $17.08. It is down -29.33% in the last 3 months and down -26.28% in the last 12 months.
Core Laboratories saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Core Laboratories's stock price’s past reactions to earnings here.
According to InvestingPro, Core Laboratories's Financial Health score is "fair performance".
Check out Core Laboratories's recent earnings performance, and Core Laboratories's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar